SRI International Inc.와 협력 계약
에사르 에너지
69.50p
16:35 09/06/14
25 4월 2024
N4제약
("N4 Pharma" 또는 "회사")
Collaboration Agreement with SRI International Inc.
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system designed to carry nucleotides to be developed as cancer treatments and vaccines, is delighted to announce that it has entered into a research collaboration agreement (the "Agreement") with SRI International, an independent nonprofit research institute based in Silicon Valley, California ("SRI") to combine Nuvec® with SRI's proprietary FOX Three Molecular Guidance System™ ("MGS") with the aim of co-marketing the resultant combined technology.
Under the Agreement, the Company will collaborate with SRI to perform research to conjugate its MGS system to Nuvec® in order to increase intracellular delivery to specific target cells. On the back of the combined technology, N4 Pharma and SRI will work collaboratively to develop and pursue new business opportunities.
SRI's MGS technology is designed to overcome cellular barriers that prevent intracellular delivery of large molecule biotherapeutics. The system uses proprietary technology that enables the delivery of macromolecular payloads to the target cell and then on to subcellular locations within those cells. SRI has developed a panel of 50 MGSs targeted at a wide variety of cell types, both diseased and healthy.
SRI has demonstrated that the MGS technology can deliver more than a dozen types of payloads - from functional enzymes, antibodies, and nucleic acids (including siRNA, ASOs, and DNA) to liposomes and nanoparticles - to targeted, intracellular molecular-target locations previously considered unreachable, and therefore, untreatable. For more information on MGS see: https://www.sri.com/platform/fox-three-molecular-guidance-system-mgs/.
The SRI Biosciences division the Company will be working with integrates basic biomedical research with drug and diagnostics discovery, and preclinical and clinical development. The team has advanced more than 200 drugs to clinical trials, and 25 have reached the market. The division is focused on novel platforms and programs in a variety of therapeutic areas targeting high unmet medical needs.
Kathlynn Brown, President of SRI's Bioscience Division, commented:
"We're excited to work with N4 Pharma to advance nucleic acid therapies and expand the number of applications of their Nuvec nanoparticle technology using the FOX Three Platform. The key properties of Nuvec, including preventing enzymatic breakdown of nucleotides and large surface area allowing multiple copy number of cargo, together with the targeting provided by MGS, may significantly enhance the use of nucleotide therapies. This partnership marks an exciting journey towards expanding treatment possibilities and transforming the landscape of biomedicine."
회사의 CEO인 Nigel Theobald는 다음과 같이 말했습니다.:
"We are delighted to be working with SRI and to have entered into this collaboration agreement. Combining our technologies successfully will lead to working with major pharma companies in the fields of oncology and vaccines with the exciting potential to develop novel products.
"SRI collaborates with a broad range of partners from small and virtual biotechnology companies to top ten pharmaceutical companies and other leading industry partners, which will give us unparalleled access to potential commercial partners on the back of any successful combined technology resulting from our research.
This marks an exciting new chapter for N4 Pharma and I look forward to providing further updates as the research work progresses, as well as on our other work streams such as oral applications of Nuvec® and the development of ECP105 for an orphan indication with Nanogenics."
About SRI
SRI is an independent, global leader in R&D with deep roots in Silicon Valley. It is a nonprofit research institute, headquartered in Menlo Park, Calif., with a rich history of supporting government and industry. Its objective is to create and deliver world-changing solutions for a safer, healthier, and more sustainable future. For more than 75 years, SRI has collaborated across technical and scientific disciplines to discover and develop groundbreaking products and technologies and bring innovations and ideas to the marketplace. Learn more at www.sri.com.
자세한 내용은 다음으로 문의하십시오.
N4제약 나이젤 테오발드, CEO 루크 케언즈, 전무이사
N4 Pharma 투자자 허브에서 직접 참여하세요 |
N4 Pharma 투자자 허브를 통해
에 가입 투자자.n4pharma.com |
SP Angel Corporate Finance LLP 지명 고문 및 공동 Broker Matthew Johnson/Caroline Rowe/Kasia Brzozowska (Corporate Finance) Vadim Alexandre/Abigail Wayne/Rob Rees(기업 중개업) | 전화 : + 44 (0) 20 3470 0470 |
터너 포프 투자(TPI) 제한 관절 Broker 앤디 태커 제임스 포프 | 전화 : + 44 (0) 20 3657 0050 |
N4 Pharma 소개
N4 Pharma는 Nuvec®이라는 고유한 실리카 나노입자 전달 시스템을 사용하여 종양학, 유전자 치료 및 백신을 위한 새로운 전달 시스템을 개발하는 전문 제약회사입니다.
N4 Pharma's business model is to partner with companies developing novel antigens in these fields to use Nuvec® as the delivery vehicle for these antigens. As these products progress through pre‐clinical and clinical programs, N4 Pharma will seek to receive upfront payments, milestone payments and ultimately royalty payments once products reach the market.
For further information on the Company visit www.n4pharma.com or sign up at 투자자.n4pharma.com.
RNS는 귀하의 IP 주소를 사용하여 약관 준수 여부를 확인하고, 귀하가 이 커뮤니케이션에 포함된 정보를 사용하는 방식을 분석하고, 그러한 분석을 익명으로 다른 사람과 상용 서비스의 일부로 공유할 수 있습니다. RNS와 런던 증권 거래소가 귀하가 제공한 개인 데이터를 사용하는 방법에 대한 자세한 내용은 개인 정보 보호 정책을 참조하십시오.